Arthritis drug sells despite concerns
507003
BEIJING, Dec. 23 -- Celebrex, a painkiller prescribed to people with arthritis, is still selling well in Shanghai even though US experts recently found an increased risk of heart attacks and strokes for patients taking high dosages of the drug.
479126
Strong drug sales provide a dose of good medicine for this pharmaceutical company.
81672
The pharmaceutical giant is selling its pain relievers and other consumer products.
45984
Drug company Pfizer said today it is continuing to promote its arthritis drug Celebrex to doctors despite reports it more than doubles the risk of heart attacks and strokes.
134047
ARTHRITIS sufferers have been told to keep taking the painkiller Celebrex despite the drug&#39;s manufacturer finding an increased risk of heart attack in users of the drug.
166500
Merck &amp; Co. pulls the drug when a study finds it doubles the risk of heart attack and strokes. Tucsonan Carolyn White feels the pain of rheumatoid arthritis in just about every major joint in her body - shoulders
353822
Momentum was growing for a fresh look at the safety of Celebrex and other pain relievers as key researchers, a congressman and European regulators said they feared such drugs might raise the risk of heart problems like those blamed on the arthritis medicine Vioxx.    Heavily advertised as an arthritis drug, Vioxx was pulled from the market last week after its maker said a study showed it doubled the risk of heart attack and stroke...
165835
Celebrex continues to sell, while Vioxx got yanked. Courts, doctors, patients, and investors will decide which approach is better.
291615
Shirley Hill takes Aleve for arthritis pain in her hands and her back &quot;as I need it -- not every day.&quot;. And she will continue to do so, despite a warning from the Food and Drug Administration
15542
Pfizer says not to worry, its arthritis pain drug Celebrex won&#39;t go the way of Vioxx. Pfizer says it won&#39;t withdraw Celebrex, its blockbuster arthritis pain medicine, despite Friday&#39;s disclosure
583563
a widely prescribed arthritis treatment - more than doubled patients&#39; risk of heart problems in a clinical study. The announcement, 11 weeks after Merck &amp; Co.
667
The Food and Drug Administration insists that until pharmaceutical giant Merck presented new information this week, there was not enough evidence to pull the arthritis drug Vioxx off the market.
51892
The withdrawal of Vioxx by competitor Merck has given Pfizer&#39;s two top arthritis drugs a huge share of the world market. But some of the same issues that forced the Vioxx withdrawal still swirl around Pfizer&#39;s Celebrex and Bextra.
182166
An anti-arthritis drug used by 84 million patients worldwide, 400,000 of them in Britain, was withdrawn from the market yesterday after trials suggested it might nearly double the risk of heart attacks and strokes.
507775
By Tricia Bishop, The Baltimore Sun  Dec. 14--One of MedImmune Inc.'s major shareholders is urging the state's flagship biotech to put itself up for sale, suggesting management hasn't made the most from its assets, which include four products on the market and about 40 in the pipeline.
57265
Merck &amp; Co.&#39;s decision to pull its Vioxx anti-arthritis drug from the markets due to severe side effects left pharmaceutical sector mixed Thursday.
672501
NEW YORK  - A drug approved for the treatment of arthritis may have a role in reducing the risk of diabetes and heart trouble developing in young obese individuals, Harvard researchers report.